{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T13:40:27Z","timestamp":1776692427915,"version":"3.51.2"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82130003"],"award-info":[{"award-number":["82130003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82270234"],"award-info":[{"award-number":["82270234"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82370223"],"award-info":[{"award-number":["82370223"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100022963","name":"Key Research and Development Program of Zhejiang Province","doi-asserted-by":"crossref","award":["2024SSYS0025"],"award-info":[{"award-number":["2024SSYS0025"]}],"id":[{"id":"10.13039\/100022963","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100022963","name":"Key Research and Development Program of Zhejiang Province","doi-asserted-by":"crossref","award":["2024SSYS0023"],"award-info":[{"award-number":["2024SSYS0023"]}],"id":[{"id":"10.13039\/100022963","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Key Project of Science and Technology Department of Zhejiang Province","award":["2024C03156"],"award-info":[{"award-number":["2024C03156"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-026-04755-6","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T22:44:22Z","timestamp":1772577862000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Anti-CD19 chimeric antigen receptor T-cell therapy for relapsed or refractory Philadelphia chromosome-positive B cell acute lymphoblastic leukemia: a multicenter retrospective study"],"prefix":"10.1186","volume":"24","author":[{"given":"Jinglei","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengmei","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingfeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Sang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Songfu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingbing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanfang","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongxian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoqing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"4755_CR1","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1056\/NEJMra2113347","volume":"386","author":"R Fo\u00e0","year":"2022","unstructured":"Fo\u00e0 R, Chiaretti S. Philadelphia chromosome\u2013positive acute lymphoblastic leukemia. N Engl J Med. 2022;386:2399\u2013411.","journal-title":"N Engl J Med"},{"key":"4755_CR2","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1182\/blood-2008-04-149286","volume":"112","author":"T Burmeister","year":"2008","unstructured":"Burmeister T, Schwartz S, Bartram CR, G\u00f6kbuget N, Hoelzer D, Thiel E. Patients\u2019 age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group. Blood. 2008;112:918\u20139.","journal-title":"Blood"},{"key":"4755_CR3","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s11912-012-0247-7","volume":"14","author":"T Liu-Dumlao","year":"2012","unstructured":"Liu-Dumlao T, Kantarjian H, Thomas DA, O\u2019Brien S, Ravandi F. Philadelphia-positive acute lymphoblastic leukemia: current treatment options. Curr Oncol Rep. 2012;14:387\u201394.","journal-title":"Curr Oncol Rep"},{"key":"4755_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-023-01409-5","volume":"16","author":"E Jabbour","year":"2023","unstructured":"Jabbour E, Short NJ, Jain N, Haddad FG, Welch MA, Ravandi F, et al. The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades. J Hematol Oncol. 2023;16:22.","journal-title":"J Hematol Oncol"},{"key":"4755_CR5","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1001\/jamaoncol.2022.2398","volume":"8","author":"E Jabbour","year":"2022","unstructured":"Jabbour E, Haddad FG, Short NJ, Kantarjian H. Treatment of Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens: A Review. JAMA Oncol. 2022;8:1340\u20138.","journal-title":"JAMA Oncol"},{"key":"4755_CR6","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1182\/blood-2016-02-700153","volume":"128","author":"P Rousselot","year":"2016","unstructured":"Rousselot P, Coud\u00e9 MM, Gokbuget N, Gambacorti Passerini C, Hayette S, Cayuela J-M, et al. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood. 2016;128:774\u201382.","journal-title":"Blood"},{"key":"4755_CR7","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1080\/14737140.2020.1832890","volume":"20","author":"M Balsat","year":"2020","unstructured":"Balsat M, Cacheux V, Carre M, Tavernier-Tardy E, Thomas X. Treatment and outcome of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults after relapse. Expert Rev Anticancer Ther. 2020;20:879\u201391.","journal-title":"Expert Rev Anticancer Ther"},{"key":"4755_CR8","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11899-017-0372-3","volume":"12","author":"S Lalit","year":"2017","unstructured":"Lalit S, Joseph B. New treatment strategies for Philadelphia chromosome-positive acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2017;12:136\u201342.","journal-title":"Curr Hematol Malig Rep"},{"key":"4755_CR9","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1002\/cncr.33321","volume":"127","author":"W Stock","year":"2021","unstructured":"Stock W, Martinelli G, Stelljes M, DeAngelo DJ, G\u00f6kbuget N, Advani AS, et al. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed\/refractory acute lymphoblastic leukemia. Cancer. 2021;127:905\u201313.","journal-title":"Cancer"},{"key":"4755_CR10","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","volume":"35","author":"G Martinelli","year":"2017","unstructured":"Martinelli G, Boissel N, Chevallier P, Ottmann O, G\u00f6kbuget N, Topp MS, et al. Complete hematologic and molecular response in adult patients with relapsed\/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol. 2017;35:1795\u2013802.","journal-title":"J Clin Oncol"},{"key":"4755_CR11","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1200\/JCO.20.02262","volume":"39","author":"NN Shah","year":"2021","unstructured":"Shah NN, Lee DW, Yates B, Yuan CM, Shalabi H, Martin S, et al. Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL. J Clin Oncol. 2021;39:1650\u20139.","journal-title":"J Clin Oncol"},{"key":"4755_CR12","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1038\/s41375-024-02319-2","volume":"38","author":"I Abou Dalle","year":"2024","unstructured":"Abou Dalle I, Moukalled N, El Cheikh J, Mohty M, Bazarbachi A. Philadelphia-chromosome positive acute lymphoblastic leukemia: ten frequently asked questions. Leukemia. 2024;38:1876\u201384.","journal-title":"Leukemia"},{"key":"4755_CR13","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1038\/s41375-021-01277-3","volume":"35","author":"NJ Short","year":"2021","unstructured":"Short NJ, Kantarjian H, Jabbour E. Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms. Leukemia. 2021;35:3044\u201358.","journal-title":"Leukemia"},{"key":"4755_CR14","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Rivi\u00e8re I, Gonen M, Wang X, S\u00e9n\u00e9chal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378:449\u201359.","journal-title":"N Engl J Med"},{"key":"4755_CR15","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. N Engl J Med. 2018;378:439\u201348.","journal-title":"N Engl J Med"},{"key":"4755_CR16","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","volume":"398","author":"BD Shah","year":"2021","unstructured":"Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398:491\u2013502.","journal-title":"Lancet"},{"key":"4755_CR17","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1200\/JCO.21.00917","volume":"39","author":"C Roddie","year":"2021","unstructured":"Roddie C, Dias J, O\u2019Reilly MA, Abbasian M, Cadinanos-Garai A, Vispute K, et al. Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2021;39:3352\u201363.","journal-title":"J Clin Oncol"},{"key":"4755_CR18","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.1182\/blood.2021013733","volume":"139","author":"Y Qi","year":"2022","unstructured":"Qi Y, Zhao M, Hu Y, Wang Y, Li P, Cao J, et al. Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL. Blood. 2022;139:3376\u201386.","journal-title":"Blood"},{"key":"4755_CR19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41409-020-0982-6","volume":"56","author":"B Gu","year":"2021","unstructured":"Gu B, Shi B-Y, Zhang X, Zhou S-Y, Chu J-H, Wu X-J, et al. Allogeneic haematopoietic stem cell transplantation improves outcome of adults with relapsed\/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia entering remission following CD19 chimeric antigen receptor T cells. Bone Marrow Transplant. 2021;56:91\u2013100.","journal-title":"Bone Marrow Transplant"},{"key":"4755_CR20","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"key":"4755_CR21","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.1182\/bloodadvances.2022009072","volume":"7","author":"L-Y Chen","year":"2023","unstructured":"Chen L-Y, Gong W-J, Li M-H, Zhou H-X, Xu M-Z, Qian C-S, et al. Anti-CD19 CAR T-cell consolidation therapy combined with CD19+ feeding T cells and TKI for Ph+ acute lymphoblastic leukemia. Blood Adv. 2023;7:4913\u201325.","journal-title":"Blood Adv"},{"key":"4755_CR22","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1182\/blood-2016-03-707562","volume":"128","author":"NJ Short","year":"2016","unstructured":"Short NJ, Jabbour E, Sasaki K, Patel K, O\u2019Brien SM, Cortes JE, et al. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2016;128:504\u20137.","journal-title":"Blood"},{"key":"4755_CR23","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/ajh.26238","volume":"96","author":"N Jain","year":"2021","unstructured":"Jain N, Maiti A, Ravandi F, Konopleva M, Daver N, Kadia T, et al. Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia. Am J Hematol. 2021;96:1000\u20137.","journal-title":"Am J Hematol"},{"key":"4755_CR24","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1182\/blood.2024023930","volume":"144","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Short NJ, Kantarjian HM, Chang T-C, Ghate PS, Qu C, et al. Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL. Blood. 2024;144:61\u201373.","journal-title":"Blood"},{"key":"4755_CR25","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1002\/ajh.25418","volume":"94","author":"S Feins","year":"2019","unstructured":"Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019;94:S3-9.","journal-title":"Am J Hematol"},{"key":"4755_CR26","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41408-024-01055-1","volume":"14","author":"C Wang","year":"2024","unstructured":"Wang C, Li J, Liu W, Zhao L, Yan H, Yan Y, et al. Refined risk stratification helps guiding transplantation choice in adult BCR::ABL1-positive acute lymphoblastic leukemia. Blood Cancer J. 2024;14:71.","journal-title":"Blood Cancer J"},{"key":"4755_CR27","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.3324\/haematol.2022.280638","volume":"107","author":"C Saygin","year":"2022","unstructured":"Saygin C, Cannova J, Stock W, Muffly L. Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients. Haematologica. 2022;107:2783\u201393.","journal-title":"Haematologica"},{"key":"4755_CR28","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1182\/blood-2011-12-399287","volume":"120","author":"N G\u00f6kbuget","year":"2012","unstructured":"G\u00f6kbuget N, Stanze D, Beck J, Diedrich H, Horst H-A, H\u00fcttmann A, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012;120:2032\u201341.","journal-title":"Blood"},{"key":"4755_CR29","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1002\/ajh.25582","volume":"94","author":"H Jiang","year":"2019","unstructured":"Jiang H, Li C, Yin P, Guo T, Liu L, Xia L, et al. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed\/refractory B-cell acute lymphoblastic leukemia: an open-label pragmatic clinical trial. Am J Hematol. 2019;94:1113\u201322.","journal-title":"Am J Hematol"},{"key":"4755_CR30","doi-asserted-by":"publisher","first-page":"e183\u201391","DOI":"10.1016\/j.bbmt.2020.04.003","volume":"26","author":"S Bouziana","year":"2020","unstructured":"Bouziana S, Bouzianas D. Exploring the dilemma of allogeneic hematopoietic cell transplantation after chimeric antigen receptor T cell therapy: to transplant or not? Biol Blood Marrow Transplant. 2020;26:e183\u201391.","journal-title":"Biol Blood Marrow Transplant"},{"key":"4755_CR31","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","volume":"133","author":"KA Hay","year":"2019","unstructured":"Hay KA, Gauthier J, Hirayama AV, Voutsinas JM, Wu Q, Li D, et al. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood. 2019;133:1652\u201363.","journal-title":"Blood"},{"key":"4755_CR32","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41409-022-01845-w","volume":"58","author":"Z Yao","year":"2023","unstructured":"Yao Z, Gu B, Zhang Y, Qi J, Chen J, Xu Y, et al. CD19 chimeric antigen receptor T-cell therapy as a bridge therapy for allogeneic hematopoietic stem cell transplantation in patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant. 2023;58:103\u20135.","journal-title":"Bone Marrow Transplant"},{"key":"4755_CR33","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13045-020-00873-7","volume":"13","author":"H Zhao","year":"2020","unstructured":"Zhao H, Wei J, Wei G, Luo Y, Shi J, Cui Q, et al. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed\/refractory acute lymphoblastic leukemia: a multi-center retrospective study. J Hematol Oncol. 2020;13:42.","journal-title":"J Hematol Oncol"},{"key":"4755_CR34","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1182\/blood.2022016194","volume":"140","author":"A Ghobadi","year":"2022","unstructured":"Ghobadi A, Slade M, Kantarjian H, Alvarenga J, Aldoss I, Mohammed KA, et al. The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis. Blood. 2022;140:2101\u201312.","journal-title":"Blood"},{"key":"4755_CR35","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1001\/jamaoncol.2025.0674","volume":"11","author":"M Zhang","year":"2025","unstructured":"Zhang M, Fu S, Feng J, Hong R, Wei G, Zhao H, et al. Dasatinib and CAR T-cell therapy in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a nonrandomized clinical trial. JAMA Oncol. 2025;11:625\u20139.","journal-title":"JAMA Oncol"},{"key":"4755_CR36","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6:224ra25.","journal-title":"Sci Transl Med"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-04755-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04755-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04755-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T11:33:48Z","timestamp":1775648028000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-04755-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4755"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-04755-6","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"assertion":[{"value":"12 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This multicenter retrospective study was approved by the Ethics Committee of The First Affiliated Hospital, Zhejiang University School of Medicine, the coordinating center (Approval No. IIT20241434A), and was conducted in accordance with the Declaration of Helsinki. The ethics committees approved a waiver of informed consent owing to the minimal risk to patients and the impracticality of obtaining consent in this retrospective study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"207"}}